VALIANTLAB share price, P/E, ROE & financials

On 6 Nov 2026, Valiant Laboratories was priced at ₹116.10, or 41.3× trailing earnings, against an industry P/E of 28.7×, and the shares are 18% below their 52-week high. Its ROCE of 0.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales fell 11% a year over 3 years. Debt is 0.15× equity. It is a small-cap company with a market cap of ₹631 Cr, ranked 80th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 42% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹116.10
Day high: ₹116.10
Day low: ₹116.10
Prev. close: ₹118.46
Volume: 3.6K

Health check

1 good · 5 to check

ReturnsAhead
+41.9% over a year, better than 5 of 7 peers.
Price tagPricier
P/E 41.3 vs industry 28.7.
GrowthShrinking
Sales −10.7% a year over 3 years.
ProfitabilityWeak
ROCE 0.8% vs peer median 17.9%.
Balance sheetStretched
Debt 0.15× equity, interest covered 1.4×, Piotroski 3 of 9.
Red flags1 to check
Return on equity is low at −1.2%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹631 Cr, #80 of 154 in its industry by size.

Moves with the market

Beta 0.81 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹306 Cr · profit ₹16 Cr

Market cap: ₹631 Cr; Small cap
P/E: 41.3; Industry 28.7
Price to book: 2.03; Peers 4.99
Dividend yield: 0.00%
ROE: −1.2%; Peers 14.7%
ROCE: 0.8%; Peers 17.9%
Debt to equity: 0.15; Debt ₹46 Cr
EPS (TTM): ₹2.81; Face value ₹10
OPM (TTM): 10.9%; Net margin 5.2%
Sales growth: +146.2%; Latest quarter vs a year ago
Profit growth: +1058.9%; Latest quarter vs a year ago
Price to sales: 2.06; EV/EBITDA 21.4

Strengths

Quarterly profit up 1058.9% on a year ago.
Quarterly sales up 146.2% on a year ago.

Risks to check

Return on equity is low at −1.2%.

Derived automatically from reported figures. Not a recommendation.

About Valiant Laboratories

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also manufactures and sells specialty chemicals and chemical intermediates, including chlorophenol…

Headquarters: Mumbai
Employees: 84
Sector: Healthcare
ISIN: INE0JWS01017
Website: valiantlabs.in

Price range

52 weeks

₹49.51₹141.38

Today

₹116.10₹116.10

Avg volume (3M): 1.3 L
1-year return: plus 41.9%
From 52-week high: minus 17.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
VALIANTLABValiant Laboratories	116.10	minus 1.99%	631	41.3	2.03	0.8%	−1.2%	10.9%	−10.7%	–	0.00%	plus 41.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
46.8	46.2	52.5	92	115
44.4	46.1	53.3	87.2	86
2.4	0.1	−0.9	4.8	29.3
5.1%	0.2%	−1.7%	5.2%	25.4%
0.7	0.9	0.6	0.2	0.9
0.1	0.1	0.7	1	1.1
0.5	0.5	2	2.9	2.9
2.4	0.3	−3	1	26.2
25.6%	27.6%	−136.0%	−68.0%	19.4%
1.8	0.2	−7.1	1.8	21.1
0.42	0.04	-1.44	0.32	3.89

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −10.7%
ROE: −1.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
334	182	133	237
–	minus 45.5%	minus 26.7%	+78.0%
299	190	135	231
35.1	−8.4	−1.4	6.6
10.5%	−4.6%	−1.1%	2.8%
0.9	5.6	3.1	1.2
0.3	0.1	0.2	1.9
1.6	2	2.1	6
3.9	4	−0.9	0.9
38.1	−0.8	−1.5	0.8
24.0%	141.5%	−45.5%	525.4%
29	0.3	−2.2	−3.3
–	minus 98.9%	minus 788.7%	–
6.19	0.12	-0.47	-0.65

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
32.6	43.5	43.5	54.3
67.9	193	191	257
60.2	76.7	122	46.2
52.3	29.1	44.9	107
213	343	401	464
61.2	114	205	233
13	63.6	156	6.1
35.4	144	76	33.1
103	21.5	−35.9	192
213	343	401	464

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
56.1	1.9	1.3	−10.4
−55.2	−144	−52.8	7.3
−0.9	152	44.7	1.8
−0.1	10.5	−6.8	−1.4
−37.7	−45.9	−114	−34.2
18.4	−44	−113	−44.6

Shareholding pattern

Source: NSE filings

74.9%

promoters

Promoters74.94%
Public25.06%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	74.94%	25.06%	0.00
30 Jun 2026	74.94%	25.06%	0.00
31 Mar 2026	74.94%	25.06%	0.00
31 Dec 2025	74.94%	25.06%	0.00
30 Sep 2025	74.94%	25.06%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you